2020-05-12T19:12:42-05:00 2019-09-30 953309779 GURSEY SCHNEIDER LLP 1888 CENTURY PARK EAST SUITE 900 LOS ANGELES CA 900671735 990 2018-10-01 954296919 INTERNATIONAL MYELOMA FOUNDATION INTE 8184877455 12650 RIVERSIDE DRIVE NO 206 NORTH HOLLYWOOD CA 916073466 SUSAN DURIE PRESIDENT 8184877455 2020-04-24 1 NAZ AFSHAR P00441843 3105520960 38.88.179.250 2020-04-24 12:04:10 PD P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 B4DE9E07BEFF9F022A478DFE9E5F2D6773821691 2018 2020-09-23 17:36:50Z SUSAN DURIE 12650 RIVERSIDE DRIVE SUITE 206 NORTH HOLLYWOOD CA 91607 20402322 0 X WWW.MYELOMA.ORG X 1990 CA DEDICATED TO IMPROVING THE QUALITY OF LIFE OF MYELOMA PATIENTS WHILE WORKING TOWARD PREVENTION AND A CURE. 17 16 48 15 0 0 16653578 20084695 59459 72368 329426 165880 -238441 -297325 16804022 20025618 423333 370000 0 0 5367547 5954445 0 0 1242145 11093027 13006481 16883907 19330926 -79885 694692 16649778 18014619 8647450 9119429 8002328 8895190 X DEDICATED TO IMPROVING THE QUALITY OF LIFE OF MYELOMA PATIENTS WHILE WORKING TOWARD PREVENTION AND A CURE. 0 0 8988911 370000 RESEARCH - THE INTERNATIONAL MYELOMA FOUNDATION (IMF) IS THE LEADER IN GLOBALLY COLLABORATIVE MYELOMA RESEARCH. IMF SUPPORTS LAB-BASED RESEARCH AND HAS AWARDED OVER 146 GRANTS TO TOP JUNIOR AND SENIOR RESEARCH SCIENTISTS SINCE 1995. IN ADDITION, IMF BRINGS TOGETHER THE WORLD'S LEADING EXPERTS IN THE MOST SUCCESSFUL AND UNIQUE WAY THROUGH THE INTERNATIONAL MYELOMA WORKING GROUP, WHICH IS PUBLISHING IN PRESTIGIOUS MEDICAL JOURNALS, CHARTING THE COURSE TO A CURE, MENTORING THE NEXT GENERATION OF INNOVATIVE INVESTIGATORS, AND IMPROVING LIVES THROUGH BETTER CARE. THE BLACK SWAN RESEARCH INITIATIVE IS A MULTINATIONAL CONSORTIUM OF LEADING MYELOMA EXPERTS WHO ARE HARNESSING NEW TECHNOLOGIES AND THE LATEST MYELOMA TREATMENTS TO FIND A PATHWAY TO A CURE. THE BLACK SWAN RESEARCH STRATEGY CAPITALIZES ON THE AVAILABILITY OF POTENT NOVEL THERAPIES AND THE ADVENT OF ULTRA-SENSITIVE TESTS TO MEASURE EXACTLY WHEN AND HOW THOSE THERAPIES ARE WORKING IN PATIENTS. THE BLACK SWAN RESEARCH INITIATIVE IS DEDICATED TO DEVELOPING NEW CURATIVE THERAPIES FOR MYELOMA. 1300134 72368 PATIENT AND FAMILY SEMINARS: THE IMF'S PATIENT AND FAMILY SEMINARS PRESENT VITAL INFORMATION ABOUT NEW TREATMENTS AND CLINICAL TRIALS, PROVIDE TIME WITH MYELOMA SPECIALISTS IN INTIMATE SETTINGS, AND ALLOW PARTICIPANTS TO SHARE THEIR PERSONAL EXPERIENCES AND SUPPORT. PREMIER MYELOMA EXPERTS VOLUNTEER THEIR TIME TO THE SEMINARS, TO EMPOWER PATIENTS AND THEIR FAMILIES TO MAKE EDUCATED TREATMENT CHOICES TAILORED TO THEIR NEEDS. IN ADDITION TO PATIENT AND FAMILY SEMINARS, THE IMF FACILITATES REGIONAL COMMUNITY WORKSHOPS, WHICH SERVE AS CONDENSED SEMINARS IN SMALLER CITIES TO EXPAND THE REACH OF IMF PROGRAMS AND UP-TO-DATE INFORMATION ON MYELOMA CARE, SUPPORT AND TREATMENT TO A WIDER AUDIENCE AT NO CHARGE. 1811101 EDUCATION AND AWARENESS: ALTHOUGH IT IS THE SECOND MOST COMMON BLOOD CANCER, MULTIPLE MYELOMA IS STILL A RELATIVELY UNKNOWN DISEASE. FOR MANY PATIENTS AND THEIR CAREGIVERS, IT IS AT DIAGNOSIS WHEN THEY FIRST HEARD THE WORD "MYELOMA". IMF RECOGNIZES THE NEED FOR COMPREHENSIVE EDUCATION PROGRAMS FOR BOTH THE PATIENT AND THE PHYSICIAN TO ENSURE THAT PATIENTS ARE DIAGNOSED CORRECTLY AND TREATED EFFECTIVELY. OUR LIBRARY OF MORE THAN 100 PUBLICATIONS FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS, IS AVAILABLE FREE OF CHARGE. PUBLICATIONS ARE UPDATED ANNUALLY AND AVAILABLE IN MORE THAN 14 LANGUAGES. THE IMF EMPOWERS PATIENTS AND THEIR CAREGIVERS TO JOIN HEALTHCARE PROVIDERS AS ACTIVE DECISION-MAKING PARTNERS, LEADING TO THE BEST POSSIBLE QUALITY OF LIFE FOR EACH INDIVIDUAL MYELOMA PATIENT. THE IMF PRODUCES COMPREHENSIVE BUT 'USER-FRIENDLY' INFORMATION FOR THE ENTIRE MYELOMA COMMUNITY. THE IMF'S PUBLICATIONS LIBRARY INCLUDES AN EXTENSIVE CATALOG OF BOOKLETS, TIP CARDS, ARTICLES, AND TELECONFERENCES, BLOGS, DIGITAL MEDIA AND INTERVIEWS, ALL WRITTEN, CREATED, AND PRODUCED BY THE IMF WITH OVERSIGHT BY ITS SCIENTIFIC ADVISORY COMMITTEE. THE IMF LIBRARY'S BROAD SCOPE INCLUDES INFORMATION ABOUT MYELOMA TREATMENT OPTIONS, CLINICAL TRIALS, AND QUALITY OF LIFE CONSIDERATIONS FOR PATIENTS AND PHYSICIANS. 5382717 INTERNATIONAL - THE IMF GROWS ITS NETWORK OF HEALTH CARE PROFESSIONALS AROUND THE WORLD. KEY TEAM MEMBERS ORGANIZE PHYSICIAN AS WELL AS PATIENT MEETINGS IN ORDER TO PROVIDE EDUCATION ABOUT THE LATEST DEVELOPMENTS IN THE FIELD OF MULTIPLE MYELOMA.SUPPORT GROUPS - THROUGH A GLOBAL COMMUNITY OF VOLUNTARY SUPPORT GROUPS, THE IMF SEEKS TO ENSURE THAT PATIENTS AND FAMILIES HAVE LOCAL ACCESS TO SUPPORT AND EDUCATION. THE IMF CURRENTLY SUPPORTS OVER 300 SUPPORT GROUPS WORLDWIDE. THE IMF OFFERS UNEQUALED WEBSITE CREATION AND HOSTING FOR LOCAL SUPPORT GROUPS, AND PROVIDED A UNIQUE OPPORTUNITY FOR SOME SUPPORT GROUP LEADERS TO ATTEND THE AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING. THE 19TH ANNUAL SUPPORT GROUP LEADERS SUMMIT TOOK PLACE WITH OVER 100 LEADERS IN ATTENDANCE. THE SUPPORT GROUPS REPRESENTED AT THE SUMMIT SERVE MORE THAN 5,500 SUPPORT GROUP MEMBERS, EXTENDING THE SUMMIT'S REACH TO THOUSANDS OF MYELOMA PATIENTS AND FAMILY MEMBERS. TECHNOLOGY IS ALSO EMPHASIZED FOR SUPPORT GROUP LEADERS. THE IMF ALSO CONTINUED TO UPDATE ITS APP SPECIFICALLY DESIGNED FOR SUPPORT GROUP LEADERS WHICH OFFER MEETING AND EDUCATION MATERIALS ACCESSIBLE TO HELP BUILD EFFECTIVE COMMUNICATION WITH PATIENTS, CAREGIVERS AND FAMILY MEMBERS.NURSE - THE IMF NURSE LEADERSHIP BOARD IS A PROFESSIONAL PARTNERSHIP REPRESENTING NURSE EXPERTS CARING FOR MYELOMA PATIENTS AT LEADING MEDICAL CENTERS. FOUNDED IN NOVEMBER 2006, THE NLB HAS PROVEN TO BE INVALUABLE TO THE MYELOMA COMMUNITY AS A PLATFORM THAT BOLSTERS NURSING EDUCATION, CLINICAL CARE EXPERIENCE EXCHANGE, AND PATIENT KNOWLEDGE AND EMPOWERMENT IN AN EFFORT TO OPTIMIZE OUTCOMES FOR PATIENTS WITH MYELOMA. THIS BOARD OF EXPERIENCED MYELOMA NURSES HAS MADE GREAT STRIDES IN IMPROVING THE NURSING CARE AND SELF-CARE OF MYELOMA PATIENTS SINCE ITS INCEPTION.CLINICAL MEETINGS - IMF TEAM MEMBERS ORGANIZE CLINICAL MEETINGS, BRINGING TOGETHER THE WORLD'S LEADING MYELOMA EXPERTS, TO FORM A COALITION THAT WILL WORK COLLABORATIVELY ON MYELOMA-RELATED PROJECTS AND AVOID DUPLICATION OF EFFORTS AND DILUTION OF VALUABLE RESOURCES. THESE COALITIONS PROMOTE EXCELLENCE IN CLINICAL PRACTICE, RESEARCH AND EDUCATION AND CME-ACCREDITED MEDICAL EDUCATION PROGRAMS. THIS PAST YEAR ALSO INCLUDED EDUCATION TO THE COMMUNITY PHYSICIAN AND NURSE VIA ONLINE AND LIVE INSTRUCTION.ADVOCACY - THE IMF IS DEDICATED TO CREATING A GLOBAL COMMUNITY THAT SUPPORTS THE WIDE-RANGING NEEDS OF ALL AFFECTED BY MYELOMA. THE IMF ADVOCATES ON BEHALF OF THOSE AFFECTED BY MULTIPLE MYELOMA FOR AN INCREASE IN ACCESSIBILITY OF HIGH-QUALITY DIAGNOSTICS AND TREATMENTS, FOR FUNDING OF MYELOMA-RELATED RESEARCH, AND FOR AN END TO INSURANCE COVERAGE DISPARITIES FOR TREATMENT. THE IMF INCLUDES THE ENTIRE MYELOMA COMMUNITY IN THESE EFFORTS AND CONTINUES TO EXPAND ITS COMMITMENT TO EMPOWERING PATIENTS, FAMILIES, AND FRIENDS TO ADVOCATE ON BEHALF OF PATIENT RIGHTS.INFOLINE - THE IMF'S TOLL-FREE INFORMATION TELEPHONE LINE PROVIDES LIFE-SAVING AND LIFE-CHANGING MYELOMA TREATMENT AND MANAGEMENT SUPPORT FROM COMPASSIONATE, HIGHLY TRAINED SPECIALISTS. AS NEW TREATMENT OPTIONS ARE GAINING ATTENTION AND USE IN MULTIPLE MYELOMA, ANSWERING QUESTIONS ABOUT MYELOMA, ITS TREATMENT, DRUG SIDE EFFECTS, OPTIONS FOR POSSIBLE CLINICAL TRIALS OTHER HEALTH CONCERNS, AND WHERE TO FIND LOCAL SUPPORT IS MORE IMPORTANT THAN EVER.WEBSITE - REDESIGNED IN EARLY 2019, THE IMF WEBSITE IS THE LEADING RESOURCE FOR MYELOMA-RELATED CONTENT AND THE MOST COMPLETE SOURCE OF ANSWERS FROM THE MANY QUESTIONS ASKED BY THOSE NEWLY DIAGNOSED TO THOSE MANAGING MYELOMA FOR MANY YEARS. THE WEBSITE CONSIDERS PATIENTS, CAREGIVERS, FAMILY MEMBERS, AND HEALTHCARE PROFESSIONALS. INFORMATION IS AVAILABLE IN MULTIPLE LANGUAGES AND FOCUS IS ON THE IMF'S RESEARCH, EDUCATION, SUPPORT AND ADVOCACY INITIATIVES.MYELOMA TODAY - MYELOMA TODAY IS A QUARTERLY NEWSLETTER AND THE GO-TO RESOURCE FOR THE MYELOMA COMMUNITY TO LEARN ABOUT THE LATEST ADVANCES IN MYELOMA TREATMENT, RESEARCH AND QUALITY OF LIFE ISSUES. IT IS PROVIDED FREE OF CHARGE.INFORMATIONAL MAILINGS - THE INFOPACK IS MADE UP OF A SELECTION OF THE IMF'S PUBLICATIONS AND IS DESIGNED TO PROVIDE NEWLY DIAGNOSED PATIENTS AND THEIR FAMILIES WITH A COMPLETE UNDERSTANDING OF THE DISEASE AND CARE. THE INFO PACK CONTAINS INFORMATIVE MATERIALS FREE OF CHARGE IN 20 LANGUAGES. 5382717 17482863 1 1 0 1 0 0 0 0 0 0 1 1 0 0 1 1 1 0 0 1 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 38 0 1 48 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 17 16 1 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 0 AL AK AZ AR CA CO CT DC FL GA HI IL KS KY ME MD MA MI MN MS MO NH NJ NM NY NC OH OK OR PA RI SC TN UT VA WA WV WI X X X JENNIFER SCARNE 8184877455 12650 RIVERSIDE DRIVE 206 NORTH HOLLYWOOD CA 91607 DR BRIAN DURIE CHAIRMAN 1.00 X 0 0 0 SUSAN DURIE PRESIDENT 40.00 X X 243242 0 36845 BENSON KLEIN DIRECTOR 1.00 X 0 0 0 DR ROBERT A KYLE DIRECTOR 1.00 X 0 0 0 DR EDITH MITCHELL DIRECTOR 1.00 X 0 0 0 CHARLES NEWMAN DIRECTOR 1.00 X 0 0 0 MATTHEW ROBINSON DIRECTOR 1.00 X 0 0 0 E MICHAEL D SCOTT DIRECTOR 1.00 X 0 0 0 LORAINE BOYLE DIRECTOR 1.00 X 0 0 0 DR VINCENT RAJKUMAR DIRECTOR 1.00 X 0 0 0 DR MARIO BOCCADORO DIRECTOR 1.00 X 0 0 0 ANDREW KUZNESKI III DIRECTOR 1.00 X 0 0 0 DR HEINZ LUDWIG DIRECTOR 1.00 X 0 0 0 CHRISTINE BATTISTINI DIRECTOR 1.00 X 0 0 0 YELAK BIRU DIRECTOR 1.00 X 0 0 0 JASON KATZ DIRECTOR 1.00 X 0 0 0 GEORGE T HAYUM DIRECTOR 1.00 X 0 0 0 JENNIFER SCARNE CFO/COO 40.00 X 264200 0 22103 DIANE MORAN STRATEGIC PLANNER 40.00 X 363025 0 18423 LISA PAIK SENIOR VICE PRESIDENT 40.00 X 190967 0 25710 JOSEPH MIKHAEL CHIEF MEDICAL OFFICER 40.00 X 450000 0 24989 PETER ANTON VICE PRESIDENT, MARKETING 40.00 X 186517 0 31021 LYNN GREEN SENIOR VICE PRESIDENT, PHILANTHROPY 40.00 X 109731 0 4130 1807682 0 163221 18 0 1 0 DAN NAVID SIRA SILA 20/46 SOI 97 HUA HIN TH 77110 INTERNATIONAL GLOBAL STRATEGY 208000 DRINKER BIDDLE & REATH LLP ONE LOGAN SQUARE STE 2000 PHILIDELPHIA PA 19103 ADVOCACY CONSULTING SERVICES 160000 NIXON PEABODY LLP PO BOX 28012 NEW YORK NY 100878012 LEGAL COUNSEL 110641 3 1099194 18985501 20084695 PATIENT & FAMILY SEMINARS 611710 36338 36338 SUPPORT GROUP 611710 36030 36030 72368 165880 165880 79379 1099194 376704 -297325 -297325 20025618 72368 0 -131445 113333 113333 256667 256667 5954445 4809359 385886 759200 109032 102174 2107 4751 63972 57032 3502 3438 1758356 1688407 666 69283 436060 407307 6621 22132 140280 124387 7300 8593 315735 229723 32563 53449 1238368 1204424 6579 27365 3209227 3068051 87956 53220 335426 307156 14116 14154 64957 61271 1237 2449 PRINTING & PUBLICATIONS 4816953 4803383 13570 POSTAGE & SHIPPING 245835 93156 3793 148886 TELEPHONE 132850 115020 2700 15130 RECRUITMENT 49624 49624 89806 42013 1268 46525 19330926 17482863 605918 1242145 548806 1329030 1566173 2624490 7041588 5710832 1287362 1038027 1209300 584896 928345 624404 5146943 6551634 130561 136202 16649778 18014619 1506735 2583802 7062437 6457610 78278 78017 8647450 9119429 X 6338900 8708329 1663428 186861 8002328 8895190 16649778 18014619 694692 198170 0 X X 0 1 X 1 0 X 12769438 11394264 9690465 11470224 19852188 65176579 12769438 11394264 9690465 11470224 19852188 65176579 33455160 31721419 128518 197754 170097 134827 371600 1002796 66179375 283051 0.47930 0.47360 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 50192 195447 245639 19085287 19330926 1000000 250000 0 0 902384 902008 946948 1000000 3751340 5627010 231437 202131 234619 245639 913826 225596 225502 236737 250000 937835 1406753 78841 39381 43144 50192 211558 1209300 584896 624404 624404 CERTIFICATES OF DEPOSIT 868922 F EQUITY SECURITIES & ETF'S 1885763 F MUTUAL FUNDS 2532396 F FIXED MATURITIES 1134675 F GIFT ANNUITIES 129878 F 6551634 ANNUITY PYMT LIABILITY 78017 78017 X 20223788 198170 198170 20025618 0 20025618 19330926 0 19330926 0 19330926 PART X, LINE 2: MANAGEMENT HAS ANALYZED THE TAX POSITIONS TAKEN BY THE ENTITY AND HAS CONCLUDED THAT AS OF SEPTEMBER 30, 2019, THERE WERE NO UNCERTAIN TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN. ACCORDINGLY, NO INTEREST OR PENALTIES RELATED TO UNCERTAIN TAX POSITIONS WERE ACCRUED IN THE ACCOMPANYING FINANCIAL STATEMENTS. THE ENTITY IS SUBJECT TO AUDITS BY TAXING JURISDICTIONS, HOWEVER, NO AUDITS FOR ANY TAX PERIODS ARE CURRENTLY IN PROGRESS. MANAGEMENT BELIEVES THAT THE ENTITY IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS FOR YEARS ENDED ON OR PRIOR TO SEPTEMBER 30, 2016 UNDER FEDERAL AND CALIFORNIA TAX JURISDICTIONS. 0 EUROPE 1 1 PROGRAM SERVICES AWARDED RESEARCH GRANTS, CONDUCTED A RESEARCH PROJECT, PATIENT & FAMILY SEMINARS, PATIENT AND PHYSICIAN REGIONAL COMMUNITY WORKSHOPS, AND AN AWARDS CEREMONY. 2892676 EAST ASIA AND THE PACIFIC 1 1 PROGRAM SERVICES AWARDED RESEARCH GRANTS, CONDUCTED A RESEARCH PROJECT, PATIENT & FAMILY SEMINARS, PATIENT AND PHYSICIAN REGIONAL COMMUNITY WORKSHOPS. 1176850 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 0 PROGRAM SERVICES CONDUCTED RESEARCH PROJECTS, PATIENT EDUCATION. 270351 MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, 0 0 PROGRAM SERVICES CONDUCTED PATIENT & FAMILY SEMINARS. 104043 SOUTH AMERICA 0 0 PROGRAM SERVICES AWARDED GRANTS AND CONDUCTED RESEARCH PROJECTS. 14000 2 2 0 0 2 2 4457920 0 4457920 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM UNRAVELING THE BALANCE OF TOLERANCE AND IMMUNOGENICITY OF MULTIPLE MYELOMA CELLS. 33333 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM METABOLISM WITHIN THE BONE MARROW MICROENVIRONMENT: TARGETS FOR MM STRATEGY. 26667 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM MANIPULATING ENDOPLASMIC RETICULUM HOMEOSTASIS AND SECRETORY CAPACITY AGAINST SYSTEMIC AL AMYLOIDOSIS. 33333 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM THE RIBONUCLEASE DIS3 IN THE DNA DAMAGE RESPONSE IN MYELOMA: A TARGETABLE PATHWAY TO PROTECT THE GENOME. 16667 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM REPROGRAMMING MM CELL METABOLISHM TO AFFECT BONE DISEASE IN MULTIPLE MYELOMA. 26667 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, TISSUE ENGINEERING OF AN ORTHOTOPIC HUMANISED BONE-ORGAN AS A PRECLINICAL PLATFORM FOR MULTIPLE MYELOMA RESEARCH. 16667 EAST ASIA AND THE PACIFIC SINGLE CELL SEQUENCING TO DISCOVER TUMOR-ASSOCIATED CHANGES IN THE BONE MICROENVIRONMENT OF MYELOMA PATIENTS: IDENTIFICATION OF PROGNOSTIC MARKERS AND NOVEL THERAPEUTIC TARGETS. 53333 EAST ASIA AND THE PACIFIC DISSECTING THE STRUCTURAL AND FUNCTIONAL HETEROGENEITY OF TERMINAL EFFECTOR CD8+T CELLS FROM MGUS AND NEWLY DIAGNOSED MM PATIENTS IN ORDER TO IDENTIFY THERAPEUTIC TARGETS AND UNLOCK THEIR ANTI-MYELOMA POTENTIAL. 33333 EUROPE (INCLUDING ICELAND & GREENLAND) PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) IN MM: PIVOTAL ROLE IN GENOMIC INSTABILITY AND DRUG RESPONSE. 16667 0 0 0 0 0 0 PART I, LINE 2: FOR RESEARCH GRANT FUNDS, REPORTS ARE PROVIDED AS PART OF THE REQUIRED GRANT COMPLIANCE PROCESS BUILT INTO THE GRANT AGREEMENT. GALA 1178573 1099194 79379 376704 1178573 1099194 79379 376704 376704 -297325 N/A 0 DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON MA 02115 042263040 IRC SEC 501(C)(3) 60000 OVERCOMING RESISTANCE TO PHARMACOLOGICAL DEGRADERS OF MYELOMA ONCOPROTEINS AND RESEARCHING FUNCTIONAL ROLE OF CORE SPLICING FACTOR DEREGULATION IN MM PATHOGENESIS MICHIGAN STATE UNIVERSITY 426 AUDITORIUM ROAD EAST LANSING MI 48824 386005984 IRC SEC 501(C)(3) 53333 TARGETING C-MYC DEGRADATION TO TREAT MULTIPLE MYELOMA 1 X 0 0 0 0 0 0 0 1 0 SUSAN DURIE PRESIDENT 223242 0 20000 0 0 0 0 0 36845 0 280087 0 0 0 JENNIFER SCARNE CFO/COO 249200 0 15000 0 0 0 0 0 22103 0 286303 0 0 0 DIANE MORAN STRATEGIC PLANNER 338025 0 25000 0 0 0 0 0 18423 0 381448 0 0 0 LISA PAIK SENIOR VICE PRESIDENT 187967 0 3000 0 0 0 0 0 25710 0 216677 0 0 0 JOSEPH MIKHAEL CHIEF MEDICAL OFFICER 450000 0 0 0 0 0 0 0 24989 0 474989 0 0 0 PETER ANTON VICE PRESIDENT, MARKETING 176517 0 10000 0 0 0 0 0 31021 0 217538 0 0 0 PART I, LINE 7 BONUSES PAID: SUSAN LAVITT NOVIS - $20,000 DIANE MORAN - $25,000 JENNIFER SCARNE - $15,000 LISA PAIK - $3,000 PETER ANTON - $10,000 FORM 990, PART VII LINE 5 CHAIRMAN, DR. BRIAN DURIE, WAS COMPENSATED $192,000 FROM THE DURIE GROUP FOR SERVICES RENDERED TO THE ORGANIZATION. FORM 990, PART VI, SECTION A, LINE 2 SUSAN NOVIS, PRESIDENT AND DR. BRIAN DURIE, CHAIRMAN ARE HUSBAND AND WIFE. FORM 990, PART VI, SECTION B, LINE 11B A COPY OF THE FORM 990 IS PROVIDED TO THE FINANCE COMMITTEE OF THE BOARD FOR REVIEW PRIOR TO FILING THE TAX RETURN. FORM 990, PART VI, SECTION B, LINE 12C THIS PROCEDURE IS PERFORMED ANNUALLY AT THE ORGANIZATION'S BOARD OF DIRECTORS RETREAT. FORM 990, PART VI, SECTION B, LINE 15 FOR KEY EMPLOYEES, A REVIEW OF COMPARABLE COMPENSATION DATA IS REVIEWED BY THE FINANCE COMMITTEE. MEMBERS OF THE FINANCE COMMITTEE APPROVE OF THE COMPENSATION PACKAGE AND WOULD NOT HAVE A CONFLICT OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENT ISSUE. THE DECISION IS DISCUSSED AND RECORDED IN THE EXECUTIVE COMMITEE AND FINANCE COMMITTEE BOARD OF DIRECTOR MEETING MINUTES. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS OF THE ORGANIZATION ARE AVAILABLE ON THE ORGANIZATION'S WEBSITE, AND UPON REQUEST. THESE DOCUMENTS HAVE BEEN PROVIDED TO A THIRD PARTY WEBSITE "CHARITY NAVIGATOR: YOUR GUIDE TO INTELLIGENT GIVING." PART XII, LINE 2C THE AUDIT OVERSIGHT COMMITTEE HAS NOT CHANGED ITS PROCESS SINCE THE PRIOR YEAR.